Fennec repays $13M convertible debt; eliminates $1.5M annual interest

FENNEC PHARMACEUTICALS INC.

Repurchased and redeemed $13M of convertible notes on Dec 18, 2024; fully retires First and Third Closing Notes.
Financed entirely from available cash; eliminates ~$1.5M in annual interest expense.
Pro forma debt facility with Petrichor is ~$19.2M, maturity Sept 2027.
Eliminates potential dilution of ~1.6 million shares from repaid notes.
CEO confirms cash sufficient to fund operations into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.